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Contents l ists avai lable at ScienceDirectEditorialThe gutekidney connection in advanced chronic kidney diseaseRecent basic and clinical ﬁndings emphasize that chronic
kidney disease (CKD) is a common disease of national signiﬁ-
cance in many developed countries. In Japan, 1 in 8 adults suf-
fers from CKD, although less than 10% of people know the term
“CKD”. CKD is asymptomatic and leads to development of end-
stage renal failure with hemodialysis and increased mortality.
The main cause of mortality in patients with end-stage renal
failure is cardiovascular events. Although this is at least partly
explained by the presence of common factors that lead to
the development of cardiovascular disease and aggravation of
kidney failure, such as hypertension, dyslipidemia, diabetes,
and aging, recently highlighted evidence clearly demonstrates
that CKD acts independently as a key risk factor of cardiovascu-
lar events and other organ damage, including cognitive disor-
ders [1,2]. This in turn strongly suggests the harmful effect of
kidney damage on other organs, such as the heart, brain, and
vessels. The remote effects or distant organ effects of the kidney
are mediated by humoral factors in the systemic circulation in
CKD patients and manifested as various complications and
increased mortality. Furthermore, as described previously, the
process of aging per se signiﬁcantly accelerates the year-by-
year development and progression of CKD. This is particularly
so in the superaging society of Japan, where people older
than 65 years now account for 26.8% of the total population.
Kidney aging results in a decrease in the estimated glomerular
ﬁltration rate (eGFR) in association with tubulointerstitial
thickening, even in healthy individuals, and CKD shows prema-
ture aging phenotypes in the kidney, accelerating kidney aging
[3]. These ﬁndings emphasize the importance of research into
solutions for CKD and the distant organ effects of CKD in an ag-
ing society. In particular, prevention of the development and
retardation of the progression of CKD, namely the maintenance
of kidney homeostasis, is beneﬁcial for the regulation of sys-
temic homeostasis and consequently for the achievement of a
long and healthy life span.
CKD results in an increase in the uremic toxin level in
plasma as the disease and aging progress. The accumulation
of uremic toxins in the body is regulated by the balance be-
tween their production and clearance by the kidney. Impor-
tantly, a developing consensus states that uremic toxins are a
consequence of not only kidney failure but also renal
pathogen-induced acceleration of the progression of CKD and
kidney aging. For example, uremic toxins derived mainly
from carbohydrates, such as glyoxal, methylglyoxal, andhttp://dx.doi.org/10.1016/j.krcp.2015.08.007
2211-9132/Copyright © 2015. The Korean Society of Nephrology. Published
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).3-deoxyglucosone, cause unfavorable posttranslational modiﬁ-
cation of proteins or DNA (referred to as glycation or the Mail-
lard reaction) and produce advanced glycation end products.
These uremic toxins themselves or the advanced glycation
end products induce glycative stress, which causes cellular
dysfunction and subsequent damage to many organs, acceler-
ating kidney damage and causing remote organ effects. Glyca-
tive stress caused by these uremic toxins in glomerular and
tubular cells is a major risk factor in the development of end-
stage renal failure in CKD patients both with and without dia-
betes. Importantly, kidney and vascular aging are positively
correlated with increased glycative stress, and the condition
is ameliorated by the antiglycative stress enzyme glyoxalase
[4]. To support this notion, glyoxalase activity is decreased
with aging, and the overexpression of glyoxalase extends life
span in wild-type Caenorhabditis elegans [5]. Another kind of
uremic toxin that is derived from amino acids, such as indoxyl
sulfate or p-cresyl sulfate, predominantly induces or alters
stress signal responses, which also contribute to the patho-
physiology of CKD and kidney aging. These include hypoxic,
oxidative stress, and endoplasmic reticulum (ER) stress re-
sponses [6,7]. Previous ﬁndings demonstrated that indoxyl sul-
fate exacerbates tubulointerstitial hypoxia via (1) demand for
oxygen consumption by oxidative stress; (2) derangement of
the hypoxia adaptive response pathway, which is mediated
by hypoxia-inducible factor; and (3) suppression of erythropoi-
etin production, which leads to renal anemia [6]. Indoxyl sul-
fate also induces the maladaptive ER stress response, namely
the unfolded protein response pathway, which results in
tubular cell apoptosis and the impairment of tubular cell prolif-
eration for repair in CKD model rats [7]. Indoxyl sulfate is
closely related to not only tubular homeostasis but also tubular
aging: It induces tubular senescence, as estimated by
senescence-associated beta-galactosidase activity and other
senescence markers [8]. Taken together, these ﬁndings indicate
that various kinds of uremic toxins that accumulate in CKD pa-
tients and the aged act as pathogenic factors, which alter pro-
tein structure and function, termed defective proteostasis, or
which induce maladaptive stress signals. They closely
contribute to not only kidney damage but also the defective
link between the kidney and distant organs. This evidence em-
phasizes that therapeutic approaches that target uremic toxins
will have beneﬁcial effects on kidney homeostasis and in the
prevention of kidney damage and aging.by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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prevent CKD and kidney aging? AST-120, an agent that reduces
serum and urinary concentrations of indoxyl sulfate, is
commercially available in Japan, Korea, and the Philippines.
AST-120 is an orally administered intestinal sorbent that ad-
sorbs uremic toxins and their precursors including indole,
which is a precursor of indoxyl sulfate. Theoretically, adsorp-
tion of uremic toxins may prolong the time to initiation of
hemodialysis and improve uremic symptoms. Recent in vivo
ﬁndings in CKD model animals demonstrated a suppressive ef-
fect of AST-120 on the progression of CKD. Two large clinical
studies were performed to conﬁrm these effects in humans:
the Evaluating Prevention of Progression in Chronic Kidney Dis-
ease studies (EPPIC-1 and EPPIC-2), which were conducted as
multinational, randomized, double-blind, safety, and efﬁcacy
trials. These trials evaluated whether the addition of AST-120
to standard therapy in patients with moderate to severe CKD
can slow the progression of renal disease, deﬁned as initiation
of dialysis, kidney transplantation, or doubling of the serum
creatinine level. Results showed no signiﬁcant difference in
time to occurrence of a primary end point event between the
AST-120 and placebo groups in either study. Although change
from baseline eGFR in the AST-120 and placebo groups did
not signiﬁcantly differ in EPPIC-1, a signiﬁcant difference was
seen in EPPIC-2 and in the pooled analysis of the two trials
[9]. In another randomized crossover study of Stage 5 predial-
ysis CKD patients, add-on AST-120 resulted in a positive change
in eGFR [10]. Although AST-120 improves uremic symptoms,
the discrepant results for the renoprotective effects of AST-
120 in these human trials may be due to poor compliance
with AST-120, which requires a relatively large amount of
intake of the reagent. Further investigations are required to
develop effective therapies targeting uremic toxins in human
patients.
A second approach to reducing uremic toxin accumulation in
the body is to suppress uremic toxin formation. Importantly, the
cutting edge technology ofmetabolomics has demonstrated that
some uremic toxins are metabolites derived from gutmicrobiota
and that the alteration of microbiota proﬁle is closely associated
with the level of uremic toxin formation. For example, indole
and p-cresol, which are precursors of indoxyl sulfate andp-cresyl
sulfate, respectively, are produced by the microbiota as a metab-
olite of aminoacids (indoxyl sulfate fromtryptophanandp-cresyl
sulfate fromtyrosine). It is the consensus thatCKDoftenalters the
microbiota proﬁle in associationwith an increase in indoxyl sul-
fate or p-cresyl sulfate as disease progresses. This is another
representative example of the remote effect of CKD, showing a
deleterious effect of kidney disease on the intestinal microbiota
with subsequent increases in uremic toxins and aggravation of
remote effects on other organs. Our group demonstrated that in
5of 6nephrectomyCKDmodel rats, a prebiotic (galacto-oligosac-
charides),which reduces the indoxyl sulfate levelbymodiﬁcation
of microbiota proﬁle in CKD, ameliorated the progression of kid-
neydamage [11]. Of note, this ameliorationofCKDprogressionby
modulation of microbiota was associated with a reduction in
tubular damage caused by ER stress. Lubiprostone, commonly
used for the treatment of constipation, also ameliorates the pro-
gression of CKD and the accumulation of uremic toxins by
improving the gut microbiota and intestinal environment [12].
These ﬁndings indicate the impact of the microbiota as a culprit
in the progression of CKD and raise the possibility of therapeutic
approaches that target themicrobiota.Meanwhile, fromthepointof view of uremic toxin formation, a low protein dietmay also be
beneﬁcial. Although the renoprotective effects of a low protein
diet are controversial, some clinical studies failed to show reno-
protection with a low protein diet in CKD patients [13]. These
ﬁndings suggest that the modulation of microbiota may be
moreeffective thana lowprotein intake in regulating aminoacid-
ederived uremic toxin formation. Taken together, these ﬁndings
indicate that the suppression of the accumulation of uremic
toxins by both absorption and decreased formation may be a
beneﬁcial approach to delaying CKD progression and kidney
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